Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 20/20 | 0.71 |
| ▸ | PDE1A | P54750 | 18/20 | 0.71 |
| ▸ | PDE1C | Q14123 | 18/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675044 | 1.00 | PDE1B (0.71) | PDE1BPDE1APDE1C | |
| SCHEMBL17674884 | 1.00 | PDE1B (0.71) | PDE1BPDE1APDE1C | |
| SCHEMBL17674916 | 0.89 | PDE1B (0.69) | PDE1BPDE1APDE1C | |
| SCHEMBL17674847 | 0.89 | PDE1B (0.69) | PDE1BPDE1APDE1C | |
| SCHEMBL17675060 | 0.89 | PDE1B (0.69) | PDE1BPDE1APDE1C | |
| SCHEMBL18185713 | 0.83 | PDE1B (1.00) | PDE1BPDE1APDE1C | |
| SCHEMBL18185758 | 0.83 | PDE1B (1.00) | PDE1BPDE1APDE1C | |
| SCHEMBL18185716 | 0.83 | PDE1B (1.00) | PDE1BPDE1APDE1C | |
| SCHEMBL17674865 | 0.78 | PDE1A (0.51) | PDE1BPDE1APDE1C | |
| SCHEMBL17675064 | 0.77 | PDE1B (0.71) | PDE1BPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204387-B1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | claimed |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-12-11 | — | — | US | claimed |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-19 | — | — | US | claimed |
| EP-3204387-A1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055618-A1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | PDE5A, PDE4A, PDE12 | PDE1B 12/4885PDE1A 10/4885PDE1C 15/4885 |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | PDE5A, PDE4A, PDE12 | PDE1B 12/4885PDE1A 10/4885PDE1C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.